Additionally,
the following are considered anti-dilutive securities excluded from weighted-average shares used to calculate diluted net loss per common
share:
SCHEDULE OF DILUTIVE NET LOSS PER COMMON SHARE
| | |
2025 | | |
2024 | |
| | |
For
the years ended December 31, | |
| | |
2025 | | |
2024 | |
| Shares subject to outstanding common
stock options | |
| - | | |
| 16 | |
| Shares subject to outstanding Series A warrants | |
| 6,647 | | |
| 6,647 | |
| Shares subject to outstanding PAW | |
| 959 | | |
| 959 | |
| Shares subject to outstanding PA Warrants | |
| 3,096 | | |
| 3,096 | |
| Shares subject to unvested stock awards | |
| 132,747 | | |
| 52 | |
| Shares subject to Outstanding Series J Warrants | |
| 2,976,192 | | |
| - | |
| Shares subject to Outstanding Series J PAW’s | |
| 104,167 | | |
| - | |
|